Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Price:
1.15 USD
-1.71%
Market Closed
Updated:
May 15, 2024
Adaptimmune Therapeutics PLC
Operating Expenses
|
Adaptimmune Therapeutics PLC
Operating Expenses Peer Comparison
Comparables:
CNTA
AUTL
BCYC
IMCR
GNS
Competitive Operating Expenses Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
|
Operating Expenses
-$191m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Operating Expenses
-$178.1m
|
CAGR 3-Years
-157%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Operating Expenses
-$177.2m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Operating Expenses
-$221.5m
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Operating Expenses
-£308m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Operating Expenses
-£620.1m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-7%
|
See Also
What is Adaptimmune Therapeutics PLC's Operating Expenses?
Operating Expenses
-191m
USD
-191m
USD
Based on the financial report for Dec 31, 2023, Adaptimmune Therapeutics PLC's Operating Expenses amounts to -191m USD.
What is Adaptimmune Therapeutics PLC's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-6%
-6%
Over the last year, the Operating Expenses growth was -1%. The average annual Operating Expenses growth rates for Adaptimmune Therapeutics PLC have been -12% over the past three years , -6% over the past five years .
You don't have any saved screeners yet
